AMPA Receptor PAM Compounds With Reduced Convulsant Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AMPA receptor modulators face challenges in effectively enhancing cognitive function while minimizing undesirable side effects such as convulsant activity, particularly in the treatment of neurological and neuropsychiatric disorders like schizophrenia and depression.
Innovation Solution
Development of novel compounds that act as positive allosteric modulators (PAMs) of AMPA receptors, specifically designed to stabilize the receptor in its active conformation, thereby increasing synaptic currents and plasticity without the risk of overstimulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AMPA receptor modulators are used to enhance cognitive function, then synaptic plasticity is improved, but convulsant activity increases
Solution Approach 1:
The patent modifies the chemical structure of AMPA receptor modulators by changing parameters such as substituting specific hydrogen atoms with fluorine or chlorine atoms, replacing methyl groups with trifluoromethyl groups, and adjusting ring structures. These parameter changes in the molecular structure allow the compounds to maintain cognitive enhancing effects while reducing convulsant activity through altered receptor binding characteristics
Solution Approach 2:
The patent introduces specific local modifications to the molecular structure at particular positions (e.g., introducing fluorine at specific ring positions, adding substituents at defined locations). These localized quality changes enable selective modulation of AMPA receptor subtypes or binding affinities, achieving cognitive enhancement with reduced convulsant side effects
2Reliability
If AMPA receptor modulators are used to treat neurological disorders, then therapeutic benefits are achieved, but side effects increase
Solution Approach 1:
The patent systematically varies chemical parameters including substituent types, positions, and molecular weights to optimize the therapeutic window. By changing these parameters, the compounds achieve better selectivity for pathological processes in neurological disorders while minimizing off-target effects that cause side effects
Solution Approach 2:
The patent acknowledges that increased receptor activation can lead to both therapeutic effects and harmful side effects. By carefully designing compounds with specific structural features, the patent converts the potential harm of over-activation into beneficial effects by achieving sustained moderate activation without peak overstimulation, thereby treating neurological disorders with reduced side effects
Data Source
AI summary
The invention provides compounds of the formula (I):wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.